Ata Janjua
About Ata Janjua
Ata Janjua is a Process Engineer III at Kite Pharma, specializing in cell therapy development. He holds a Master of Science in Applied Biomedical Engineering from Johns Hopkins University and has extensive experience in quality assurance and pharmaceutical manufacturing.
Current Role at Kite Pharma
Ata Janjua serves as a Process Engineer III at Kite Pharma, a position he has held since 2022. His work is based in Frederick, Maryland, where he contributes to the development and manufacturing processes of innovative cell therapies. His role involves applying engineering principles to optimize production processes, ensuring efficiency and compliance with industry standards.
Previous Experience in Pharmaceutical Industry
Prior to his current role, Ata Janjua gained extensive experience in the pharmaceutical industry. He worked as a Cell Therapy Specialist at Kite Pharma from 2018 to 2019, focusing on cell therapy processes. He also spent three years as a Process Automation Engineer at Bristol Myers Squibb, where he contributed to automation solutions in manufacturing. His previous roles include Quality Assurance Associate at Siegfried Holding AG and various positions at Loma Linda University.
Educational Background in Engineering and Biology
Ata Janjua holds a Master of Science in Applied Biomedical Engineering from Johns Hopkins Whiting School of Engineering, which he completed from 2020 to 2023. He also earned a Bachelor’s Degree in Biology from the University of California, Riverside, from 2012 to 2016. His education has provided him with a strong foundation in both engineering principles and biological sciences.
Experience in cGMP Environments
Ata Janjua has significant experience working in ISO 5, ISO 7, and ISO 8 cGMP environments. These environments are essential for maintaining sterile conditions in pharmaceutical manufacturing. His expertise in these areas is critical for ensuring the quality and safety of cell therapies.
Involvement in CAR-T Cell Therapy Development
Ata Janjua has been involved in the development of CAR-T cell therapies, specifically targeting Large B-Cell Lymphoma, a type of non-Hodgkin lymphoma. His work in this area highlights his contributions to advancing treatment options in the field of oncology.